The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2017:
42 negotiations are currently underway with 6 new files added since the last update of May 31, 2017:
Caprelsa (vandetanib): Used to treat medullary thyroid cancer
Kyprolis (carfilzomib): Used to ... Read More
11
Jul2017
15
Jun2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of May 31, 2017:
43 negotiations are currently underway with 9 new files added since the last update of April 30, 2017:
Brivlera (brivarcetam): Used to treat partial-onset seizures
Butrans (buprenorphine): Used to treat ... Read More
13
Jun2017
The Minister of Health and Social Services has authorized one additional update to the List of Medications covered by the basic prescription drug insurance plan and the List of Medications – Institutions in 2018: February 1. The submission deadline for innovative drug products is August 11, 2017.
Please note that only ... Read More
09
Jun2017
On June 9, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 122) describing the following changes.
1. Revised Advanced Notification Process for CADTH Common Drug Review
Drugs Undergoing Expedited Health Canada Review
Effective immediately, the mandatory advance notification requirement for drugs that are ... Read More
09
Jun2017
On June 2, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released new submission guidelines, including a pre-NOC review procedure, to be implemented immediately. Topics to be covered include:
New Pre-NOC Review Procedure & Submission Criteria
New Submission Guidelines
New Submission Requirements
Potential Changes to List ... Read More
06
Jun2017
On June 2, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released new submission guidelines, including a pre-NOC review procedure, to be implemented immediately.
Pre-NOC Review
Moving forward, INESSS will evaluate certain drug products (see the criteria here on the INESSS website) before a Notice of Compliance ... Read More
30
May2017
Consultation on Potential Changes to the Patented Medicines Regulations
On May 16, 2017, the Honourable Jane Philpott, Minister of Health, outlined a comprehensive plan for improving the pharmaceutical system in Canada. Included in the plan was the launch of a consultation process on potential changes to the Patented Medicines Regulations (Regulations) ... Read More
25
May2017
On Tuesday, May 16, 2017, Federal Health Minister Hon. Jane Philpott opened consultations on a suite of amendments to the Patented Medicines Regulations that will have significant effects on how patented drug prices are regulated in Canada. The implementation of these proposed amendments could represent the most important changes in ... Read More
16
May2017
Health Minister Hon. Jane Philpott Announces Consultations on proposed changes to the Patented Medicines Regulations
Speaking today at the Economic Club of Canada in Ottawa, Federal Health Minister Jane Philpott announced the opening of a consultation period concerning proposed changes to the Patented Medicines Regulations that would have significant effects ... Read More
16
May2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2017:
38 negotiations are currently underway with 9 new files added since the last update of March 31, 2017:
Cosentyx (secukinumab): Use to treat psoriatic arthritis
Cosentyx (secukinumab): Used to treat ... Read More